PHAXIAM Therapeutics S.A.
DelistedCIK 1624422fmd_11MVWT1HSSYES82Y6QDPX6ZQX6Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2015 to Jun 30, 2023, 14 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Research and development | 11 | 20 | 25 | 33 | 52 | 58 | 45 | 20 |
| Operating income | (16) | (22) | (31) | (44) | (64) | (69) | (57) | (3) |
| Interest expense | 0 | 0 | 3 | 0 | 2 | 5 | 3 | 1 |
| Income before taxes | – | – | – | – | – | (73) | (54) | 0 |
| Income tax expense | (0) | 0 | (0) | 0 | (0) | 0 | 0 | 1 |
| Net income from continuing operations | – | – | – | – | – | (73) | (54) | (0) |
| Net income | (15) | (22) | (34) | (38) | (63) | (73) | (54) | (0) |